Canada Pension Plan Investment Board maintained its position in Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 841,500 shares of the company’s stock at the end of the second quarter. Canada Pension Plan Investment Board’s holdings in Novo Nordisk A/S were worth $36,092,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mycio Wealth Partners LLC raised its position in Novo Nordisk A/S by 0.8% in the first quarter. Mycio Wealth Partners LLC now owns 20,280 shares of the company’s stock valued at $695,000 after buying an additional 155 shares in the last quarter. Bessemer Group Inc. raised its position in Novo Nordisk A/S by 0.7% in the second quarter. Bessemer Group Inc. now owns 33,388 shares of the company’s stock valued at $1,431,000 after buying an additional 247 shares in the last quarter. Global X Management Co. LLC raised its position in Novo Nordisk A/S by 0.3% in the first quarter. Global X Management Co. LLC now owns 103,297 shares of the company’s stock valued at $3,541,000 after buying an additional 283 shares in the last quarter. Headinvest LLC raised its position in Novo Nordisk A/S by 0.3% in the second quarter. Headinvest LLC now owns 110,025 shares of the company’s stock valued at $4,719,000 after buying an additional 310 shares in the last quarter. Finally, Shamrock Asset Management LLC raised its position in Novo Nordisk A/S by 3.3% in the first quarter. Shamrock Asset Management LLC now owns 10,378 shares of the company’s stock valued at $356,000 after buying an additional 334 shares in the last quarter. Institutional investors own 6.40% of the company’s stock.

Novo Nordisk A/S (NYSE NVO) opened at 45.81 on Friday. The stock has a market cap of $113.68 billion, a price-to-earnings ratio of 18.74 and a beta of 0.63. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $47.98. The firm’s 50 day moving average price is $42.76 and its 200 day moving average price is $38.81.

The firm also recently disclosed an annual dividend, which will be paid on Tuesday, August 29th. Shareholders of record on Monday, August 21st will be issued a $0.336 dividend. This is an increase from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date is Friday, August 18th. This represents a yield of 1.07%. Novo Nordisk A/S’s dividend payout ratio is presently 36.00%.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/novo-nordisk-as-nysenvo-stake-held-by-canada-pension-plan-investment-board/1477402.html.

Several research firms recently commented on NVO. Zacks Investment Research lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. TheStreet upgraded Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Finally, BidaskClub upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, June 15th. Five equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $53.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.